Key result
In cancer patients, the incidence of DVT was 16.7% with prophylaxis, while LMWH treatment for existing DVT resulted in a 66% resolution rate, 10% pulmonary embolism rate, and 3.3% mortality.
Why the study?
Deep vein thrombosis is often silent in hospitalized patients with nonspecific signs and symptoms, warranting an evaluation of recent management trends and fatal complications in cancer patients.
Does low molecular weight heparin (LMWH) safely and effectively prevent and manage deep vein thrombosis in cancer patients?
Cohort (n=60)
No
Does low molecular weight heparin (LMWH) safely and effectively prevent and manage deep vein thrombosis in cancer patients?
LMWH prophylaxis and treatment in cancer patients is effective for managing and preventing deep vein thrombosis and its complications.
LMWH prophylaxis and treatment show incomplete protection in cancer; leaves open optimal regimens pending randomized trials.
ObjectiveTo focus on the recent trends in the management of deep vein thrombosis (DVT) in malignancy as well as its fatal complications.BackgroundDVT is usually silent in nature in most of the hospitalized patients and is usually presented by nonspecific symptoms and signs.Patients and methodsA prospective study was carried out on 60 patients at Ahmed Maher Teaching Hospital between 2017 and 2018. The patients were divided into two groups: the first group composed of 30 cancer patients on whom prophylactic measures against venous thromboembolism was applied for 8 months and the second group composed of 30 cancer patients with a history of DVT and who had undergone management and follow-up for 3–6 months. Full history, routine, physical examination, routine investigations, and coagulation profile were done.ResultsThe mean age of the prevention group was 54.87 ± 11.34 and 59.10 ± 12.50 in the management group. The incidence of DVT was 16.7%. In the management group, the rate of resolution of DVT without complications after being treated with low molecular weight heparin (LMWH) for 6 months was 66. The rate of cases developed pulmonary embolism from the management group was 10%. The rate of deaths due to DVT and its complications was 3.3%.ConclusionLMWH prophylaxis in patients undergoing cancer-related surgery has proved to be effective and safe in reducing the risk of an acute event. Thromboprophylaxis with LMWH, unfractionated heparin, and mechanical methods should be considered for all patients with a malignancy who undergo surgery.
No takes yet. Share an insight, caveat, or question.
Shaat et al. (2019) conducted a cohort in Cancer and deep vein thrombosis (n=60). Low molecular weight heparin (LMWH) was evaluated on Incidence of DVT, resolution of DVT, pulmonary embolism, and death. In cancer patients, the incidence of DVT was 16.7% with prophylaxis, while LMWH treatment for existing DVT resulted in a 66% resolution rate, 10% pulmonary embolism rate, and 3.3% mortality.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: